NCT07378306 2026-04-21
FACT-TN
Sun Yat-sen University
Phase 2 Recruiting
Clinical Trials
10 trialsNCT07383818 2026-02-03
Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT06178159 2025-10-01
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT07169994 2025-09-12
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT06611813 2025-08-12
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT06914440 2025-07-15
Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer
Xijing Hospital
Phase 2 Recruiting
NCT06977893 2025-05-18
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
First Affiliated Hospital of Zhejiang University
Phase 3 Recruiting
NCT06964906 2025-05-11
NeoHunter
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06642545 2025-02-17
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT06389006 2024-05-23
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting